Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2021 07:45 ET | Source: Adagene Inc.

Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to...
August 26, 2021 07:45 ET | Source: Adagene Inc.

Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates

- Established three clinical collaborations with Merck to conduct global combination trials with pembrolizumab for three clinical-stage oncology candidates - - Evidence of ADG106 efficacy with...
August 19, 2021 07:00 ET | Source: Adagene Inc.

Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)

SAN FRANCISCO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and...
August 12, 2021 07:45 ET | Source: Adagene Inc.

Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board

SAN FRANCISCO, Calif. and SUZHOU, China, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company...
July 22, 2021 07:45 ET | Source: Adagene Inc.

Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)

SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and...
July 07, 2021 07:45 ET | Source: Adagene Inc.

Adagene Announces Authorization of Share Repurchase Program up to US$20 Million

SAN FRANCISCO and SUZHOU, China, July 07, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
June 16, 2021 07:45 ET | Source: Adagene Inc.

Adagene 宣佈納入 FTSE Russell 指數

美國三藩市和中國蘇州, June 16, 2021 (GLOBE NEWSWIRE) -- Adagene Inc.（下稱「 Adagene」）(Nasdaq: ADAG) 是一家平台驅動的臨床階段生物製藥公司，致力改革基於抗體的新型免疫療法的發現和開發，今天宣佈將納入全球股票指數系列（「 GEIS」）中，包括富時全球全市場指數 (FTSE Global Total Cap Index)...
June 16, 2021 07:45 ET | Source: Adagene Inc.

天演药业宣布纳入FTSE Russell指数

旧金山和中国苏州, June 16, 2021 (GLOBE NEWSWIRE) -- 天演药业有限公司（以下简称为“天演药业”）（纳斯达克股票代码：ADAG）是一家平台驱动型临床阶段生物制药公司，致力于改变新型抗体免疫疗法的发现和开发。该公司今天宣布，其将被添加到富时全球股权指数体系（以下简称为“GEIS”），包括富时全球总市值指数和富时新兴全盘指数，并将于6月21日生效。 FTSE...
June 16, 2021 07:45 ET | Source: Adagene Inc.

Adagene Announces Inclusion in FTSE Russell Indexes

SAN FRANCISCO and SUZHOU, China, June 16, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
May 25, 2021 16:05 ET | Source: Adagene Inc.

Adagene to Present at Upcoming Investor Conferences

SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to...